BRPI0815360A2 - Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto - Google Patents

Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto

Info

Publication number: BRPI0815360A2
Authority: BR; Brazil
Prior art keywords: pyrimidinosulfamide; pharmaceutical composition; composition containing; derivative compound; pair preparation
Prior art date: 2007-08-17

Application number

BRPI0815360-4A2A

Other languages

English (en)

Inventor

Martin Bolli

Christoph Boss

Alexander Treiber

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-17

Filing date

2008-08-15

Publication date

2015-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40140023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0815360(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-08-15 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2015-02-10 Publication of BRPI0815360A2 publication Critical patent/BRPI0815360A2/pt

2017-12-26 Publication of BRPI0815360A8 publication Critical patent/BRPI0815360A8/pt

2018-12-04 Publication of BRPI0815360B1 publication Critical patent/BRPI0815360B1/pt

2021-05-25 Publication of BRPI0815360B8 publication Critical patent/BRPI0815360B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Cardiology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Transplantation (AREA)

BRPI0815360A 2007-08-17 2008-08-15 composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto BRPI0815360B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IB2007053292		2007-08-17
IB2008052571		2008-06-26
PCT/IB2008/053282 WO2009024906A1 (en)	2007-08-17	2008-08-15	4-pyrimidinesulfamide derivative

Publications (4)

Publication Number	Publication Date
BRPI0815360A2 true BRPI0815360A2 (pt)	2015-02-10
BRPI0815360A8 BRPI0815360A8 (pt)	2017-12-26
BRPI0815360B1 BRPI0815360B1 (pt)	2018-12-04
BRPI0815360B8 BRPI0815360B8 (pt)	2021-05-25

Family

ID=40140023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0815360A BRPI0815360B8 (pt)	2007-08-17	2008-08-15	composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto

Country Status (31)

Country	Link
US (1)	US8324232B2 (pt)
EP (1)	EP2190837B1 (pt)
JP (1)	JP5323075B2 (pt)
KR (1)	KR101528946B1 (pt)
CN (1)	CN101772494B (pt)
AR (1)	AR070018A1 (pt)
AU (1)	AU2008290234B2 (pt)
BR (1)	BRPI0815360B8 (pt)
CA (1)	CA2695511C (pt)
CY (2)	CY1113255T1 (pt)
DK (1)	DK2190837T3 (pt)
ES (1)	ES2394584T3 (pt)
FI (1)	FIC20240041I1 (pt)
FR (1)	FR24C1047I2 (pt)
HR (1)	HRP20120878T1 (pt)
HU (1)	HUS2400041I1 (pt)
IL (1)	IL203936A (pt)
LT (1)	LTC2190837I2 (pt)
MA (1)	MA31702B1 (pt)
MX (1)	MX2010001837A (pt)
MY (1)	MY152281A (pt)
NL (1)	NL301304I2 (pt)
NO (1)	NO2024053I1 (pt)
NZ (1)	NZ583990A (pt)
PL (1)	PL2190837T3 (pt)
PT (1)	PT2190837E (pt)
RU (1)	RU2485116C2 (pt)
SI (1)	SI2190837T1 (pt)
TW (1)	TWI411437B (pt)
WO (1)	WO2009024906A1 (pt)
ZA (1)	ZA201001872B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2907811A1 (en) *	2014-02-14	2015-08-19	Actelion Pharmaceuticals Ltd.	Process for manufacturing pyrimidine sulfamide derivatives
WO2017093903A1 (en) *	2015-11-30	2017-06-08	Laurus Labs Private Limited	An improved process for the preparation of macitentan
WO2017191565A1 (en) *	2016-05-04	2017-11-09	Shilpa Medicare Limited	Process for preparation of macitentan
EP3658140B1 (en) *	2017-02-27	2025-05-21	Idorsia Pharmaceuticals Ltd	Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension
MY210547A (en) *	2017-11-30	2025-09-30	Idorsia Pharmaceuticals Ltd	Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
CN108997223B (zh) *	2018-08-09	2020-06-30	浙江先锋科技股份有限公司	5-(4-溴苯基)-4，6-二氯嘧啶的制备方法
SMT202400274T1 (it)	2018-12-21	2024-09-16	Actelion Pharmaceuticals Ltd	Macitentan per il trattamento di ipertensione arteriosa polmonare
TW202042818A (zh)	2019-01-25	2020-12-01	瑞士商艾克泰聯製藥有限公司	用於治療慢性血栓性肺高血壓之醫藥組成物
CN114630668B (zh) *	2019-11-07	2024-02-27	苏州科睿思制药有限公司	一种Aprocitentan晶型及其制备方法和用途
WO2021237004A1 (en)	2020-05-21	2021-11-25	Teva Pharmaceuticals International Gmbh	Solid state forms of aprocitentan and process for preparation thereof
CN114644595A (zh) *	2020-12-19	2022-06-21	普济生物科技（台州）有限公司	阿普昔腾坦的无定型态、其药物组合物和用途
WO2023111797A1 (en) *	2021-12-17	2023-06-22	Janssen Biotech, Inc.	Pyrimidine sulfamide derivatives and process for manufacturing them
JP2025519101A (ja)	2022-05-22	2025-06-24	イドルシア・ファーマシューティカルズ・リミテッド	高血圧の治療のための４－ピリミジンスルファミド誘導体の使用
AU2023275935A1 (en)	2022-05-25	2025-01-09	Idorsia Pharmaceuticals Ltd	Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
CN119330888B (zh) *	2024-10-25	2025-11-28	上海药坦药物研究开发有限公司	一种阿普昔腾坦的制备方法
CN119504609A (zh) *	2024-11-27	2025-02-25	成都启晟合研医药科技有限公司	一种阿普昔腾坦的中间体化合物、阿普昔腾坦及其制备方法
CN119528821B (zh) *	2024-11-29	2025-10-10	浙江国邦药业有限公司	一种阿普昔腾坦的制备方法
CN119528820B (zh) *	2024-11-29	2025-10-10	浙江国邦药业有限公司	一种阿普昔腾坦的合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2801584A1 (de)	1978-01-14	1979-07-19	Bayer Ag	Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
JPH04103525A (ja)	1990-08-22	1992-04-06	Sanwa Kagaku Kenkyusho Co Ltd	難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en)	1993-06-28	2000-06-21	Hoffmann La Roche	Novel Sulfonylamino Pyrimidines
US5523204A (en)	1993-12-10	1996-06-04	Becton Dickinson And Company	Detection of nucleic acids in cells by strand displacement amplification
WO1996016963A1 (de)	1994-11-25	1996-06-06	F. Hoffmann-La Roche Ag	Sulfonamide und deren verwendung als heilmittel
TW313568B (pt)	1994-12-20	1997-08-21	Hoffmann La Roche
US5739333A (en)	1995-05-16	1998-04-14	Tanabe Seiyaku Co., Ltd.	Sulfonamide derivative and process for preparing the same
TW442301B (en)	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
WO1997022595A1 (en)	1995-12-20	1997-06-26	Yamanouchi Pharmaceutical Co., Ltd.	Arylethenesulfonamide derivatives and drug composition containing the same
US20010014352A1 (en)	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
TWI284642B (en)	1999-01-18	2007-08-01	Hoffmann La Roche	Novel heterocyclic sulfonamides
ES2295048T3 (es)	1999-09-03	2008-04-16	Actelion Pharmaceuticals Ltd.	Bis-sulfonamidas.
CA2389479A1 (en)	1999-12-22	2001-06-28	Christoph Boss	Butyne diol derivatives
US20040062803A1 (en)	1999-12-22	2004-04-01	Hedden David B.	Sustained-release formulation of a cyclooxygenase-2 inhibitor
EP1244657B1 (en)	1999-12-31	2004-12-29	Encysive Pharmaceuticals Inc.	Sulfonamides and derivatives thereof that modulate the activity of endothelin
AU2001263850A1 (en)	2000-04-20	2001-11-07	Actelion Pharmaceuticals Ltd	Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (en)	2000-04-25	2001-11-01	Actelion Pharmaceuticals Ltd	Substituted sulfonylaminopyrimidines
JP2001335469A (ja)	2000-05-26	2001-12-04	Lion Corp	固体製剤の製造方法
IL153688A0 (en)	2000-06-28	2003-07-06	Teva Pharma	Carvedilol
MXPA03005120A (es)	2000-12-07	2004-03-10	Cv Therapeutics Inc	Compuestos para el incremento de abca-1.
WO2002053557A1 (en) *	2000-12-18	2002-07-11	Actelion Pharmaceuticals Ltd	Novel sulfamides and their use as endothelin receptor antagonists
FR2819720B1 (fr)	2001-01-22	2004-03-12	Fournier Lab Sa	Nouveaux comprimes de fenofibrate
KR20030041577A (ko)	2001-11-20	2003-05-27	디디에스텍주식회사	난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
PL208114B1 (pl)	2002-02-26	2011-03-31	Astrazeneca Ab	Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
EP1569914B1 (en) *	2002-12-02	2009-02-18	Actelion Pharmaceuticals Ltd.	Pyrimidine-sulfamides and their use as endothelian receptor antagonist
WO2004075894A1 (en)	2003-02-25	2004-09-10	Eli Lilly And Company	Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
WO2007031933A2 (en) *	2005-09-12	2007-03-22	Actelion Pharmaceuticals Ltd	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es)	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
CN101939001B (zh)	2008-02-20	2012-06-20	埃科特莱茵药品有限公司	用于治疗卵巢癌的含有紫杉醇的组合
ES2763176T3 (es)	2008-08-13	2020-05-27	Actelion Pharmaceuticals Ltd	Composiciones terapéuticas que contienen macitentan

2008
- 2008-02-07 MX MX2010001837A patent/MX2010001837A/es active IP Right Grant
- 2008-08-14 AR ARP080103552A patent/AR070018A1/es not_active Application Discontinuation
- 2008-08-15 EP EP08807330A patent/EP2190837B1/en active Active
- 2008-08-15 DK DK08807330.9T patent/DK2190837T3/da active
- 2008-08-15 US US12/673,413 patent/US8324232B2/en active Active
- 2008-08-15 WO PCT/IB2008/053282 patent/WO2009024906A1/en not_active Ceased
- 2008-08-15 HR HRP20120878AT patent/HRP20120878T1/hr unknown
- 2008-08-15 MY MYPI20100680 patent/MY152281A/en unknown
- 2008-08-15 NZ NZ583990A patent/NZ583990A/en unknown
- 2008-08-15 JP JP2010520674A patent/JP5323075B2/ja active Active
- 2008-08-15 KR KR1020107004945A patent/KR101528946B1/ko active Active
- 2008-08-15 PL PL08807330T patent/PL2190837T3/pl unknown
- 2008-08-15 PT PT08807330T patent/PT2190837E/pt unknown
- 2008-08-15 SI SI200830785T patent/SI2190837T1/sl unknown
- 2008-08-15 CA CA2695511A patent/CA2695511C/en active Active
- 2008-08-15 AU AU2008290234A patent/AU2008290234B2/en active Active
- 2008-08-15 RU RU2010109543/04A patent/RU2485116C2/ru active
- 2008-08-15 CN CN2008801016796A patent/CN101772494B/zh active Active
- 2008-08-15 BR BRPI0815360A patent/BRPI0815360B8/pt active IP Right Grant
- 2008-08-15 ES ES08807330T patent/ES2394584T3/es active Active
- 2008-08-15 TW TW097131323A patent/TWI411437B/zh active
2010
- 2010-02-14 IL IL203936A patent/IL203936A/en active IP Right Grant
- 2010-03-12 MA MA32692A patent/MA31702B1/fr unknown
- 2010-03-16 ZA ZA2010/01872A patent/ZA201001872B/en unknown
2012
- 2012-10-25 CY CY20121101015T patent/CY1113255T1/el unknown
2024
- 2024-11-27 HU HUS2400041C patent/HUS2400041I1/hu unknown
- 2024-12-02 FI FIC20240041C patent/FIC20240041I1/fi unknown
- 2024-12-03 NO NO2024053C patent/NO2024053I1/no unknown
- 2024-12-04 CY CY2024031C patent/CY2024031I2/el unknown
- 2024-12-04 LT LTPA2024534C patent/LTC2190837I2/lt unknown
- 2024-12-05 FR FR24C1047C patent/FR24C1047I2/fr active Active
- 2024-12-10 NL NL301304C patent/NL301304I2/nl unknown

Also Published As

Publication number	Publication date
CA2695511A1 (en)	2009-02-26
CN101772494B (zh)	2013-05-15
CA2695511C (en)	2015-11-03
RU2485116C2 (ru)	2013-06-20
EP2190837A1 (en)	2010-06-02
HK1144196A1 (en)	2011-02-02
SI2190837T1 (sl)	2012-11-30
BRPI0815360A8 (pt)	2017-12-26
CY1113255T1 (el)	2016-04-13
PT2190837E (pt)	2012-10-31
HUS2400041I1 (hu)	2024-12-28
LTPA2024534I1 (pt)	2024-12-27
TWI411437B (zh)	2013-10-11
NZ583990A (en)	2012-06-29
NO2024053I1 (no)	2024-12-03
PL2190837T3 (pl)	2013-01-31
RU2010109543A (ru)	2011-09-27
WO2009024906A1 (en)	2009-02-26
DK2190837T3 (da)	2012-10-08
EP2190837B1 (en)	2012-08-15
AR070018A1 (es)	2010-03-10
CN101772494A (zh)	2010-07-07
US8324232B2 (en)	2012-12-04
HRP20120878T1 (hr)	2012-11-30
ZA201001872B (en)	2011-05-25
AU2008290234B2 (en)	2013-11-21
JP2010536742A (ja)	2010-12-02
KR101528946B1 (ko)	2015-06-15
FR24C1047I1 (fr)	2025-01-10
FR24C1047I2 (fr)	2025-10-10
BRPI0815360B1 (pt)	2018-12-04
MA31702B1 (fr)	2010-09-01
MY152281A (en)	2014-09-15
ES2394584T3 (es)	2013-02-04
KR20100052517A (ko)	2010-05-19
NL301304I2 (nl)	2024-12-19
MX2010001837A (es)	2010-03-10
US20120142716A1 (en)	2012-06-07
TW200927122A (en)	2009-07-01
IL203936A (en)	2016-03-31
FIC20240041I1 (fi)	2024-12-02
AU2008290234A1 (en)	2009-02-26
JP5323075B2 (ja)	2013-10-23
CY2024031I1 (el)	2026-02-25
BRPI0815360B8 (pt)	2021-05-25
LTC2190837I2 (pt)	2026-04-27
CY2024031I2 (el)	2026-02-25

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-12-26	B25A	Requested transfer of rights approved	Owner name: IDORSIA PHARMACEUTICALS LTD (CH)
2018-01-23	B25L	Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled	Owner name: ACTELION PHARMACEUTICALS LTD (CH)
2018-01-30	B25C	Requirement related to requested transfer of rights	Owner name: ACTELION PHARMACEUTICALS LTD (CH)
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-05-02	B25A	Requested transfer of rights approved	Owner name: IDORSIA PHARMACEUTICALS LTD (CH)
2018-07-03	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2018-11-06	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2018-12-04	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/12/2018, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI0815190A2 (pt)	2015-03-31	Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0918359A2 (pt)	2015-12-15	composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0818533A2 (pt)	2017-06-06	composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0821004A2 (pt)	2015-06-16	Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BRPI0617159A2 (pt)	2015-01-06	COMPOSTOS DE PIRIDOPIRIMIDINONE INIBIDORES DE PI3Ka, COMPOSIÇÕES QUE OS CONTEM E PROCESSO PARA PREPARO
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0818804A2 (pt)	2015-04-22	Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
BRPI0816331A2 (pt)	2015-04-14	Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0822946A2 (pt)	2015-06-23	Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida
BRPI0611956A2 (pt)	2018-07-31	composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
BRPI0811635A2 (pt)	2014-11-11	Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0814611A2 (pt)	2015-01-27	Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0815405A2 (pt)	2015-02-03	Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
BRPI0814308A2 (pt)	2015-02-03	Processo para o preparo de um complexo solúvel de composto resveratrol e ciclodextrina, complexo composto resveratrol e ciclodextrina, composição nutracêutica, composição farmacêutica, e uso do referido complexo
BRPI0818459A2 (pt)	2015-04-14	Composição farmacêutica adequada para uso oftálmico.
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0820673A2 (pt)	2015-06-16	Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal
BRPI0917661A2 (pt)	2015-12-01	produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0914371A2 (pt)	2019-09-24	"composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0907892A2 (pt)	2015-07-28	Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
BRPI0810399A2 (pt)	2014-11-04	Composto, composição farmacêutica que o contém e uso do mesmo